CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 74 enrolled
Drug / intervention
Fesoterodinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03946124
NCT03946124Phase 4Completed
CompareCT.gov

Prevention of Fall in Older Adults With Overactive Bladdar

University of Pennsylvania·interventional·Posted May 10, 2019·Updated May 6, 2023

In Brief

A Phase 4 clinical trial evaluating Fesoterodine for Overactive Bladder. Completed, enrolled 74 participants.

Detailed Summary

Though OAB treatment may improve physical activity, there is a lack of easily administered instruments for measuring physical activity in older adults. Aim is to validate instruments to measure physical activity and preference for medication, and to determine the effect of preference for anti-cholinergic medication on adherence, physical activity, and falls risk. It's plan a prospective cohort study of adults aged 65 or older with OAB undergoing treatment with anti-cholinergic medication.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder
Countries--
CollaboratorsPfizer

Timeline

Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 10, 2019
Enrollment StartJul 25, 2015
Primary CompletionJul 19, 2017
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 7.1 years ago

Interventions

Fesoterodinedrug

Fesoterodine, the drug used in this study, is an appropriate medication for routine and standard care of overactive bladder.